retatrutide trial safety A new clinical from Eli Lilly and Company suggests its experimental triple hormone drug, retatrutide, could become one of the next major medications in the rapidly growing weight loss and diabetes A Study of Retatrutide (LY3437943)
Pay in 4 interest-free payments of $6.26 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 6 - Aug 11






























